L3VLUP
ProSign in

VRTX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VRTXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VRTX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterVRTXJNJ
Q3 202031 holders, $21.9bn30 holders, $26.2bn
Q4 202030 holders, $18.4bn32 holders, $26.6bn
Q1 202131 holders, $15.4bn31 holders, $25.3bn
Q2 202130 holders, $12.7bn37 holders, $25.6bn
Q3 202135 holders, $10.1bn40 holders, $24.1bn
Q4 202128 holders, $12.4bn33 holders, $25.2bn
Q1 202223 holders, $16.1bn35 holders, $28.2bn
Q2 202225 holders, $18.1bn33 holders, $26.9bn
Q3 202222 holders, $18.4bn36 holders, $25.4bn
Q4 202228 holders, $18.4bn35 holders, $27.6bn
Q1 202326 holders, $21.4bn42 holders, $24.5bn
Q2 202327 holders, $24.7bn38 holders, $25.0bn
Q3 202333 holders, $24.3bn37 holders, $18.9bn
Q4 202332 holders, $28.6bn31 holders, $19.0bn
Q1 202431 holders, $29.8bn32 holders, $19.7bn
Q2 202429 holders, $33.4bn35 holders, $20.4bn
Q3 202427 holders, $33.5bn28 holders, $22.3bn
Q4 202426 holders, $28.5bn37 holders, $20.4bn
Q1 202521 holders, $35.4bn32 holders, $20.5bn
Q2 202521 holders, $32.3bn31 holders, $18.4bn
Q3 202522 holders, $25.9bn32 holders, $23.7bn
Q4 202526 holders, $31.8bn29 holders, $27.8bn
Q1 202625 holders, $31.8bn34 holders, $35.6bn
Q2 202626 holders, $34.6bn33 holders, $39.1bn
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VRTX (4)

Baillie Gifford & Co, Hudson Bay Capital Management LP, Renaissance Technologies LLC, Two Sigma Investments LP

Only JNJ (11)

Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Markel Group Inc, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →